Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939771 | 0.84 | GAA (0.40) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL12405369 | 0.83 | POLB (0.40) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL27943774 | 0.81 | ACHE (0.36) | TSHR | |
| SCHEMBL17515598 | 0.81 | TSHR (0.45) | GAAALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL18759661 | 0.80 | TSHR (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL16047 | 0.80 | TSHR (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1331297 | 0.80 | TSHR (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL11765179 | 0.79 | GAA (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL11025207 | 0.79 | CYP1A2 (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL31218556 | 0.79 | TSHR (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230202973-A1 | BARNESIN A, DERIVATIVES AND USES THEREOF | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. (HKI) (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-10011555-B2 | Methods of treating Parkinson's disease | UNIVERSITY OF MACAU (CN) | 2018-07-03 | — | — | US | disclosed |
| US-9957228-B2 | Process of production of 7,8-dihydro-C15-aldehyde | DSM IP ASSETS B.V. (NL) | 2018-05-01 | — | — | US | disclosed |
| US-20110306637-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090023903-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROALKYL-PHENYL AND HETEROCYCLIC SULFONAMIDES | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-7442833-B2 | Triphenylethylene compounds as selective estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070111971-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306637-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MGAM 2149/4885GAA 344/4885SI 2032/4885 |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MGAM 2727/4885GAA 1010/4885SI 239/4885 |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | MGAM 2489/4885GAA 168/4885SI 409/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | MGAM 997/4885GAA 1487/4885SI 818/4885 |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | MGAM 4500/4885GAA 1057/4885SI 1443/4885 |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | MGAM 3465/4885GAA 4502/4885SI 1717/4885 |
| US-20230202973-A1 | BARNESIN A, DERIVATIVES AND USES THEREOF | SERPINB1, SERPINA3, CMA1 | MGAM 1664/4885GAA 495/4885SI 273/4885 |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | PDK1, PDK2, PDK4 | MGAM 1503/4885GAA 1121/4885SI 3271/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | MGAM 1189/4885GAA 319/4885SI 2/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | MGAM 4286/4885GAA 1262/4885SI 3628/4885 |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | MGAM 2041/4885GAA 69/4885SI 346/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MGAM 2648/4885GAA 3659/4885SI 2277/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | MGAM 2931/4885GAA 1728/4885SI 1570/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | MGAM 3982/4885GAA 3445/4885SI 3740/4885 |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | RPS4X, RPS4Y1, CACNA1A | MGAM 1006/4885GAA 1902/4885SI 273/4885 |
| US-20070111971-A1 | Novel compounds | GPER1, ESR2, ESR1 | MGAM 4490/4885GAA 2208/4885SI 2942/4885 |
| US-10011555-B2 | Methods of treating Parkinson's disease | PARK7, SNCA, NLN | MGAM 1571/4885GAA 77/4885SI 1245/4885 |
| US-20090023903-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROALKYL-PHENYL AND HETEROCYCLIC SULFONAMIDES | SULT2A1, SULT1A1, SULT1E1 | MGAM 2356/4885GAA 3111/4885SI 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.